Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | July 01, 2019 | July 02, 2019 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director | October 04, 2019 | October 05, 2019 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 27, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date July 01, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.01 · Expires 2029-06-30 | Direct | 9,000 |
Reported balance
After 2019-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-01 · Grant · Acquired 9,000 · Balance 9,000 |
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 7,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
aTYR PHARMA INC
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 779,143 |
Reported balance
After 2026-05-27 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 100,000 · Balance 779,143 F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.4907 to $0.50 per share. The Reporting Person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,413,023 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,413,023 F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. |
| Common StockSEC Table I · non-derivative | Direct | 8,890 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,890 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.4907 to $0.50 per share. The Reporting Person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F2: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000.
F3: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 28, 2026 20:12 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 100,000 | $0.50 | $49,630.00 |
DisclosureSEC source: 0001236447-26-000006 · ownership.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 779,143 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.4907 to $0.50 per share. The Reporting Person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:08 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001236447-26-000003 · ownership.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| October 09, 2025 Filed Oct 9, 2025 22:30 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 317,999 | $0.94 | $299,364.26 |
DisclosureSEC source: 0001193125-25-236131 · ownership.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,413,023 F3 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.93 to $0.95 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 22:30 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 682,001 | $0.90 | $612,436.90 |
DisclosureSEC source: 0001193125-25-236131 · ownership.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,095,024 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $0.8536 to $0.95 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:23 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062945 · ownership.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| July 24, 2024 Filed Jul 24, 2024 21:29 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 52,300 | $1.93 | $101,038.37 |
DisclosureSEC source: 0000950170-24-086159 · ownership.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 413,023 F4 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.88 to $1.96 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:29 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 6,648 | $1.82 | $12,074.76 |
DisclosureSEC source: 0000950170-24-086159 · ownership.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 360,723 F3 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.775 to $1.86 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 21:29 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 41,052 | $1.74 | $71,500.27 |
DisclosureSEC source: 0000950170-24-086159 · ownership.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 354,075 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.71 to $1.78 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:16 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-064218 · ownership.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:32 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-031020 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 10, 2023 Filed May 11, 2023 13:00 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 200,000 | $2.25 | $450,000.00 |
DisclosureSEC source: 0001209191-23-028607 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 313,023 F1 · price: Represents weighted average price for the shares. The shares were purchased ranging from $2.245 to $2.25 per share under the issuer's "at-the-market" offering program implemented pursuant to the issuer's Open Market Sale Agreement with Jefferies LLC. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:54 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026067 · doc4.xml · derivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: The RSUs fully vested one year from the grant date which was April 26, 2022. F5 · derivative.expiration_date: The RSUs fully vested one year from the grant date which was April 26, 2022. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:54 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026067 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. F2 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026094 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. F2 · derivative.expiration_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:19 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057339 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 679,143 F2 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:19 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057339 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890 Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:19 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 250,000 | $8.00 | $2,000,000.00 |
DisclosureSEC source: 0001209191-21-057339 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,890 F1 · shares: Represents shares purchased in an underwritten public offering at a public offering price of $8.00 per share. F1 · price: Represents shares purchased in an underwritten public offering at a public offering price of $8.00 per share. Read SEC document |
| May 18, 2021 Filed May 20, 2021 12:55 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 50,000 | $3.98 | $199,000.00 |
DisclosureSEC source: 0001209191-21-034293 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 113,023 F2 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $3.95 to $4.00 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 00:13 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-029126 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2031-04-28 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) April 28, 2022 or (ii) the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:13 UTC | aTYR PHARMA INC LIFE · Entity 7233 | SaleCommon Stock | 8,447 | $3.64 | $30,738.63 |
DisclosureSEC source: 0001209191-20-031886 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 429,143 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.605 to $3.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:14 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-20-027995 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 16:58 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 254,000 | $4.25 | $1,079,500.00 |
DisclosureSEC source: 0001209191-20-008205 · doc4.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 437,590 F1 · shares: Represents shares purchased in an underwritten public offering at a public offering price of $4.25 per share. F1 · price: Represents shares purchased in an underwritten public offering at a public offering price of $4.25 per share. F2 · ownership.nature: There shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:11 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052613 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $72.01 | $0.00 |
DisclosureSEC source: 0001735276-19-000065 · edgardoc.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:22 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033657 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:35 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001209191-19-029051 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 20:31 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantCommon Stock | 1,848,428 | $0.54 | $999,999.55 |
DisclosureSEC source: 0001209191-19-024764 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,570,242 F2 · shares: Represents shares acquired in a registered direct offering pursuant to a Securities Purchase Agreement, dated April 10, 2019, entered between aTyr Pharma, Inc. and the investors named therein. Pursuant to the terms of the Securities Purchase Agreement, investors purchased shares of common stock at a purchase price of $0.541 per share. F2 · price: Represents shares acquired in a registered direct offering pursuant to a Securities Purchase Agreement, dated April 10, 2019, entered between aTyr Pharma, Inc. and the investors named therein. Pursuant to the terms of the Securities Purchase Agreement, investors purchased shares of common stock at a purchase price of $0.541 per share. F3 · ownership.nature: These shares are owned directly by Schimmel Revocable Trust U/A Dtd 9/6/2000. The Reporting Person and his spouse are trustees of the Schimmel Revocable Trust U/A Dtd 9/6/2000. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 00:12 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 147,225 | $0.54 | $79,795.95 |
DisclosureSEC source: 0001209191-18-060168 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 882,302 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.5404 to $0.5422 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 20,749 | $0.76 | $15,709.07 |
DisclosureSEC source: 0001209191-18-049509 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 735,077 F3 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.7488 to $0.76 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 22,000 | $0.72 | $15,752.00 |
DisclosureSEC source: 0001209191-18-049509 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 714,328 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.6999 to $0.72 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 89,275 | $0.76 | $67,482.97 |
DisclosureSEC source: 0001209191-18-049077 · doc4.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 692,328 F3 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.72 to $0.7626 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 75,136 | $0.72 | $54,090.41 |
DisclosureSEC source: 0001209191-18-049077 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,053 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.715 to $0.72 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:55 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039417 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:19 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $105.26 | $0.00 |
DisclosureSEC source: 0001735276-18-000032 · edgardoc.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document |
| May 18, 2018 Filed May 21, 2018 22:50 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 150,000 | $1.00 | $149,445.00 |
DisclosureSEC source: 0001209191-18-032107 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 527,917 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.9837 to $1.00 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:38 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-18-030949 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · derivative · entry 8 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,823 | $0.00 Strike: $63.86 | $0.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · derivative · entry 7 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,823 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. F3 · derivative.exercise_date: The stock option vests as to 25% on 3/31/2014 and as to an additional 25% of the shares granted at the end of each subsequent quarter. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $59.25 | $0.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · derivative · entry 6 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 27,823 | $150.00 | $4,173,450.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · nonDerivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 15,000 | $59.25 | $888,750.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · nonDerivative · entry 3 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,823 | $63.86 | $180,276.78 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 23:39 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 10,000 | $30.09 | $300,900.00 |
DisclosureSEC source: 0001553878-18-000020 · edgardoc.xml · nonDerivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2017. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 00:22 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseWarrant to Purchase Common Stock · Derivative | 35,376 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001209191-17-051472 · doc4.xml · derivative · entry 4 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 35,376 Underlying: Common Stock · 35,376 shares Expires 2019-12-31 F1 · shares: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel, which was incorrectly reported as Paul R. Schimmel Prototype PSP on past Form 4s filed by the Reporting Person. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 00:22 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 94,336 | $2.65 | $249,990.40 |
DisclosureSEC source: 0001209191-17-051472 · doc4.xml · nonDerivative · entry 2 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 377,917 F1 · shares: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F2 · ownership.nature: These shares are owned directly by Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel. The Reporting Person is the sole owner of the Paul Schimmel Prototype PSP, Paul Schimmel Trustee, FBO Paul Schimmel, which was incorrectly reported as Paul R. Schimmel Prototype PSP on past Form 4s filed by the Reporting Person. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:59 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $71.99 | $0.00 |
DisclosureSEC source: 0001553878-17-000029 · edgardoc.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document |
| May 09, 2017 Filed May 11, 2017 23:09 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-031645 · doc4.xml · derivative · entry 1 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionSeries G Preferred Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · derivative · entry 9 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schimmel Revocable Trust Paul R. Schimmel, Trustee Cleo Schimmel, Trustee U/A dtd 9/6/2000 Disclosed balance after: 0 Underlying: Common Stock · 3,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionSeries G Preferred Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · derivative · entry 8 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul Schimmel Prototype PSP Paul R. Schimmel, TTEE U/A dtd 01/01/1999 FBO Paul Schimmel Disclosed balance after: 0 Underlying: Common Stock · 3,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 21:34 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | ConversionSeries F Preferred Stock · Derivative | 28,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-027905 · doc4.xml · derivative · entry 7 SCHIMMEL PAUL · CIK 0001236447 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NFS/FMTC FBO Paul Schimmel Rollover IRA Disclosed balance after: 0 Underlying: Common Stock · 4,117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.exercise_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. F1 · derivative.expiration_date: Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-6.9 basis. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.